Burning Rock Biotech Stock to Reverse Split on Wednesday, May 15th (NASDAQ:BNR)

Burning Rock Biotech Limited (NASDAQ:BNR)’s stock is going to reverse split on Wednesday, May 15th. The 1-10 reverse split was announced on Wednesday, May 15th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, May 15th.

Burning Rock Biotech Price Performance

BNR opened at $0.85 on Monday. Burning Rock Biotech has a 1 year low of $0.57 and a 1 year high of $3.25. The company has a market capitalization of $87.24 million, a price-to-earnings ratio of -0.96 and a beta of 0.23. The firm’s fifty day moving average price is $0.77 and its two-hundred day moving average price is $0.86.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.22) earnings per share for the quarter. Burning Rock Biotech had a negative net margin of 121.79% and a negative return on equity of 71.77%. The firm had revenue of $17.05 million for the quarter.

Institutional Trading of Burning Rock Biotech

An institutional investor recently raised its position in Burning Rock Biotech stock. Kynam Capital Management LP raised its stake in Burning Rock Biotech Limited (NASDAQ:BNR) by 2.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,694,426 shares of the company’s stock after acquiring an additional 194,426 shares during the quarter. Burning Rock Biotech makes up 0.9% of Kynam Capital Management LP’s holdings, making the stock its 20th biggest position. Kynam Capital Management LP owned approximately 8.47% of Burning Rock Biotech worth $8,086,000 as of its most recent filing with the Securities & Exchange Commission. 30.03% of the stock is owned by institutional investors and hedge funds.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.